MPN Patient Symposium Videos
Every year, CR&T hosts the International Patient Symposium on Myeloproliferative Neoplasms (MPNs). This full-day educational event takes place in New York City, and is an opportunity for patients and caregivers to learn about the latest developments in MPN research and treatment. Each year, the program features presentations by distinguished basic scientists and clinical research physicians from the world’s leading MPN centers.
If you weren’t able to attend previous symposia, or if you attended and would like to view the talks again, you can watch these presentations at your convenience.
13th International Patient Symposium on Myeloproliferative Neoplasms
CR&T was proud to host the 13th International Patient Symposium on Myeloproliferative Neoplasms on Wednesday, October 23, 2024, at Weill Cornell Medicine in New York City. We are deeply grateful to our generous sponsors for making this program possible.
Corporate Sponsors: Incyte (Diamond Sponsor); Karyopharm Therapeutics; PharmaEssentia; Sobi (Gold Sponsors); GSK; Morphosys; Protagonist Therapeutics (Silver Sponsors); Silence Therapeutics; Sumitomo Pharma; Takeda (Bronze Sponsors)
Individual and Foundation Sponsors: Mr. & Mrs. David & Laine Boule; Victor Frankiv – in honor of Ghaith Abu-Zeinah, MD; Inessa Gold; Debra and Donald Sciaretta – in honor of Ghaith Abu-Zeinah, MD; Ms. Diane Sherman – in honor of Terry Hermanson; M.A. and Chip Quinn – in honor of Ghaith Abu-Zeinah, MD; Herman Goldman Foundation
The program featured presentations by distinguished basic scientists and clinical research physicians from the world’s leading MPN centers, which you can view below.
Welcome to CR&T's 13th International Symposium on MPNs
Dr. Ghaith Abu-Zeinah (Weill Cornell Medicine, New York, NY and Patient Symposium Chair and Medical Advisory Board Member, CR&T.) welcomes guests to the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024.
Origins and Genetics of MPNs
Dr. Linda Resar (Mount Sinai Hospital, New York, NY) discusses Origins and Genetics of MPNs at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024. Dr. Resar is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Inflammation in the MPNs
Dr. Hans Hasselbalch (Zealand University Hospital, Roskilde) discusses Inflammation in the MPNs at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024. Dr. Hasselbalch is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Cardiovascular Health in MPN Patients
Dr. Stephanie Feldman (Weill Cornell Medicine, New York, NY) discusses Cardiovascular Health in MPN Patients at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024. Dr. Feldman is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Symptom Relief, Diet, and Exercise in MPN Patients
Dr. Ruben Mesa (Wake
Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC) discusses Symptom Relief, Diet, and Exercise in MPN Patients at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024. Dr. Mesa is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
MPN Progression: Is it predictable?
Dr. Ghaith Abu-Zeinah (Weill Cornell Medicine, New York, NY) discusses MPN Progression: Is it predictable? at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024.
Accelerated and Blast-Phase MPNs
Dr. Raajit Rampal (Memorial Sloan Kettering Cancer Center, New York, NY) discusses Accelerated and Blast-Phase MPNs at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024. Dr. Rampal is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Drugs-Novel Agents for MPNs in 2024
Dr. Naveen Pemmaraju (MD Anderson Cancer Center, Houston, Tx) discusses Drugs-Novel Agents for MPNs in 2024 at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024. Dr. Pemmaraju is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Moderated Q&A
Dr. Ghaith Abu-Zeinah (Weill Cornell Medicine, New York, NY) moderates the Question & Answer session with Symposium faculty at the 13th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2024.
12th International Patient Symposium on Myeloproliferative Neoplasms
CR&T was proud to host the 12th International Patient Symposium on Myeloproliferative Neoplasms on Wednesday, November 1, 2023, at Weill Cornell Medicine in New York City. We are deeply grateful to our generous sponsors for making this program possible.
Corporate Sponsors: Incyte (Diamond Sponsor); Protagonist Therapeutics (Diamond Sponsor); CTI; PharmaEssentia; GSK; Karyopharm Therapeutics; Morphosys; Silence Therapeutics
Foundation and Individual Sponsors: Herman Goldman Foundation, Laine and David Boule, Regine Neiders, Susan And David Lemerman, Gordana Vlahovic
The program featured presentations by distinguished basic scientists and clinical research physicians from the world’s leading MPN centers, which you can view below.
Drivers of Progression of MPNs
Dr. Ronald Hoffman (Icahn School of Medicine at Mount Sinai, New York, NY) discusses Drivers of Progression of MPNs at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Hoffman is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Managing Essential Thrombocythemia in 2023
Dr. Joseph Scandura (Weill Cornell Medicine, New York, NY) discusses Managing Essential Thrombocythemia in 2023 at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Scandura is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Inflammation in the MPNs
Dr. Naveen Pemmaraju (MD Anderson Cancer Center, Houston, Tx) discusses Promising New Drugs for MPN Therapy at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Scandura is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Managing Polycythemia Vera in 2023
Dr. Richard T. Silver (Weill Cornell Medicine, New York, NY) discusses Managing Polycythemia Vera in 2023 at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Silver is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Inflammation in MPNs
Dr. Angela Fleischman (University of California, Irvine) discusses Inflammation in MPNs at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Fleischman is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Managing Myelofibrosis in 2023
Dr. Jerry L. Spivak (Johns Hopkins University School of Medicine, Baltimore, MD) Managing Myelofibrosis in 2023 at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Spivak is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
The Microbiomes in the MPNs
Dr. Hans Hasselbalch (Zealand University Hospital, Roskilde) discusses The Microbiomes in the MPNs at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Hasselbalch is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Demystifying bone marrow transplant for MPNs
Dr. Roni Tamari (Memorial Sloan Kettering Cancer Center, New York, NY) discusses Managing Demystifying bone marrow transplant for MPNs at the 12th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2023. Dr. Tamari is introduced by Dr. Ghaith Abu-Zeinah, Patient Symposium Chair and Medical Advisory Board Member, CR&T.
Moderated Q & A Session
Dr. Ghaith Abu-Zeinah (Weill Cornell Medicine, New York, NY), Patient Symposium Chair and Medical Advisory Board Member, CR&T, moderates a Q & A Session at Cancer Research & Treatment Fund’s 12th International Patient Symposium on MPNs.
11th International Patient Symposium on Myeloproliferative Neoplasms – A Virtual Event
CR&T was proud to host the Virtual 11th International Patient Symposium on Myeloproliferative Neoplasms on Wednesday, October 28, 2020.
We are deeply grateful to our generous sponsors for making this program possible.
Corporate Sponsors: Incyte (Presenting Sponsor); PharmaEssentia; and Specialdocs Consultants.
Individual Sponsors: Bharat and Milan Shah; Laine and David Boule
The program featured presentations by distinguished basic scientists and clinical research physicians from the world’s leading MPN centers, which you can view below.
Presentations,
Part 1
- Welcome & Introduction – Richard T. Silver, MD, Lewis C. Cantley, PhD (Weill Cornell Medicine, New York, NY) and David Boule, Patient Committee Chair, Cancer Research & Treatment Fund (CR&T)
- Inflammation in MPNs: Clinical and Therapeutic Aspects – Hans Hasselbalch, MD, Roskilde Hospital, Roskilde, Denmark
- Next Generation Sequencing in Diagnosis and Treatment – Joseph M. Scandura, MD, Weill Cornell Medicine, New York, NY
- Polycythemia Vera: Interferon Prolongs Myelofibrosis-Free and Overall Survival – Ghaith Abu-Zeinah, MD, Weill Cornell Medicine, New York, NY
Presentations,
Part 2
- Current Management, New Treatments, New Drugs in the Pipeline, and Evolution of Myelofibrosis – Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai, New York, NY
- Current Management of Essential Thrombocythemia – Ellen Ritchie, MD, Weill Cornell Medicine, New York, NY
- Thrombotic, Vascular, and Bleeding Complications in the MPNs – Andrew I. Schafer, MD, Weill Cornell Medicine, New York, NY
General Q&A Session
Moderator: Richard T. Silver, MD, Weill Cornell Medicine, New York, NY
Panelists: Ghaith Abu-Zeinah, MD (Weill Cornell Medicine); Hans Hasselbalch, MD (Roskilde Hospital, Roskilde, Denmark); Ronald Hoffman, MD (Icahn School of Medicine at Mount Sinai, New York, NY); Ellen Ritchie, MD (Weill Cornell Medicine); Joseph M. Scandura, MD (Weill Cornell Medicine); Andrew I. Schafer, MD (Weill Cornell Medicine)
10th International Patient Symposium on Myeloproliferative Neoplasms
CR&T was proud to host the 10th International Patient Symposium on Myeloproliferative Neoplasms on Wednesday, October 23, 2019, at Weill Cornell Medicine in New York City. We are deeply grateful to our generous sponsors for making this program possible.
Corporate Sponsors: Incyte (Presenting Sponsor); PharmaEssentia; the SASS Foundation for Medical Research, Inc.; and Sierra Oncology.
Individual Sponsors: Laine and David Boule
The program featured presentations by distinguished basic scientists and clinical research physicians from the world’s leading MPN centers, which you can view below.
Summary of MPN Research Presented at the 2018 American Society of Hematology Annual Meeting and 2019 Updates
Dr. Andrew I. Schafer (Weill Cornell Medicine, New York, NY) summarizes MPN research presented at the 2018 Annual Meeting of the American Society of Hematology and provides 2019 updates at the 10th International Symposium on Myeloproliferative Neoplasms, New York City, October 23, 2019.
Immunotherapy
Dr. Hans Hasselbalch (Roskilde Hospital, University of Copenhagen, Denmark) discusses the latest developments in immunotherapy for myeloproliferative neoplasms (MPNs) at the 10th International Patient Symposium on Myeloproliferative Neoplasms (MPNs) in New York City, October 23, 2019.
Why Patients with Polycythemia Vera and Myelofibrosis Should Be Treated with Interferon Early Rather than Late
Dr. Richard T. Silver (Weill Cornell Medicine, New York City) discusses why patients with polycythemia vera and myelofibrosis should be treated with interferon early rather than late at the 10th International Patient Symposium on Myeloproliferative Neoplasms (MPNs), October 23, 2019.
Current Management of Myelofibrosis
Dr. Ronald Hoffman (Icahn School of Medicine at Mount Sinai, New York, NY) discusses the current management of myelofibrosis at the 10th International Patient Symposium on Myeloproliferative Neoplasms (MPNs) in New York City on October 23, 2019.
Essential Thrombocythemia: A Case Study
Dr. Jerry L. Spivak (Johns Hopkins University School of Medicine, Baltimore) discusses essential thrombocythemia at the 10th International Patient Symposium on Myeloproliferative Neoplasms on October 23, 2019 in New York City.
Current State of Stem Cell Transplants in MPN Therapy
Dr. Koen van Besien (Weill Cornell Medicine, New York, NY) discusses the current state of stem cell transplants in MPN therapy at the 10th International Patient Symposium on Myeloproliferative Neoplasms on October 23, 2019 in New York City.
New MPN Treatments and Drugs
Dr. Srdan Verstovsek (University of Texas MD Anderson Cancer Center, Houston) discusses new MPN treatments and drugs at the 10th International Patient Symposium on Myeloproliferative Neoplasms on October 23, 2019 in New York City.
Diet, Exercise, and Mindfulness
Dr. Robyn Scherber (UT Health San Antonio MD Anderson Cancer Center) discusses diet, exercise, and mindfulness for people living with myeloproliferative neoplasms (MPNs).
9th International Patient Symposium on Myeloproliferative Neoplasms
CR&T was proud to host the 9th International Patient Symposium on Myeloproliferative Neoplasms on Tuesday, November 1, 2017, at Weill Cornell Medical College in New York City. We are deeply grateful to our generous sponsors for making this program possible.
Corporate Sponsors: Incyte (Presenting Sponsor); PharmaEssentia; and the SASS Foundation for Medical Research, Inc.
Individual Sponsors:
Platinum Sponsors: Mr. and Mrs. Myron J. Schuster; Silver Sponsors: Mr. and Mrs. Philip and Laureen Hidalgo; Bronze Sponsors: Laine and David Boule, Hande Taylin Or, Debra and Christopher Seiter; Donors: John Katz and Annete Albro Katz, Mr. and Mrs. Melvyn Oppenheim, Anonymous.
The program featured presentations by distinguished basic scientists and clinical research physicians from the world’s leading MPN centers, which you can view below.
NATURAL HISTORY AND HEREDITY
Dr. Jerry L. Spivak (Johns Hopkins University School of Medicine, Baltimore) discusses natural history and heredity at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017. Dr. Spivak is introduced by Dr. Richard T. Silver, Vice President and Medical Director, CR&T.
BIOMARKERS AND MOLECULAR ABNORMALITIES: WHAT DO PATIENTS NEED TO KNOW?
Dr. Alison Moliterno (Johns Hopkins University School of Medicine, Baltimore) discusses biomarkers and molecular abnormalities at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017.
CURRENT MANAGEMENT OF POLYCYTHEMIA VERA
Dr. Richard T. Silver (Weill Cornell Medicine, New York City) discusses current management of polycythemia vera (PV) at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017
CURRENT MANAGEMENT OF ESSENTIAL THROMBOCYTHEMIA
Dr. Carlos Besses (Hospital del Mar, Barcelona, Spain) discusses current management of essential thrombocythemia (ET) at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017.
CURRENT MANAGEMENT OF MYELOFIBROSIS
Dr. Ronald Hoffman (Icahn School of Medicine at Mount Sinai, New York City) discusses current management of myelofibrosis at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017.
CURRENT DEVELOPMENTS IN STEM CELL TRANSPLANTATION IN THE MPNS
Dr. Koen van Besien (Weill Cornell Medicine, New York City) discusses the latest developments in stem cell transplantation at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017
SUMMARY OF DRUGS IN CURRENT AND FUTURE CLINICAL TRIALS
Dr. Jason Gotlib (Stanford University School of Medicine, Stanford, CA) discusses new drugs in current and future clinical trials at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017.
WHAT SHOULD YOU EXPECT FROM YOUR MPN TREATMENT?
Dr. Ruben A. Mesa (UT Health San Antonio Cancer Center, TX) discusses what to expect from your MPN treatment at the 9th International Symposium on Myeloproliferative Neoplasms, New York City, November 1, 2017.
Watch Interviews with MPN Experts
Andrew Schorr of PatientPower.info, the online cancer community, conducted Facebook Live interviews with MPN experts at the Symposium, which you can view below. (Please note that you must have a Facebook account to access the videos.)
8th International Patient Symposium on Myeloproliferative Neoplasms
CR&T was proud to host the 8th International Patient Symposium on Myeloproliferative Neoplasms on Tuesday, November 4, 2015. This full-day educational event, which takes place every two years, was held at the Belfer Research Building at Weill Cornell Medical College in New York City. The Symposium enables patients and their families to learn about the latest developments in MPN research and treatment. We are deeply grateful to our generous sponsors for making this event possible.
Corporate Sponsors: Incyte Corporation (Presenting Sponsor); Gilead; The SASS Foundation for Medical Research, Inc.; and Seattle Genetics.
Individual Sponsors:
Platinum Sponsors: Mr. and Mrs. Myron J. Schuster; Gold Sponsors: Paul and Susan Saltzman; Silver Sponsors: Mr. and Mrs. Keith Civil, Christopher and Debra Seiter; Bronze Sponsors: Laine and David Boule, Matthew and Nancy Crean, Terry Hermanson, Emily and Alan Legum, Bashi and Sam Nierenberg, Hande Taylin Or.
The program featured presentations by distinguished basic scientists and clinical research physicians from the world’s leading MPN centers, which you can view below.
GENETICS OF MPNS: FROM INITIATION TO PROGRESSION
Presented by Robert Kralovics, PhD, Research Center for Molecular Medicine of The Austrian Academy of Science, Vienna, Austria
LABORATORY APPROACHES TO STUDYING MPNS
Presented by Anne M. Mullally, MD, Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA
CURRENT DEVELOPMENTS IN POLYCYTHEMIA VERA TREATMENT: IS IT CURABLE?
Presented by Richard T. Silver, MD, Weill Cornell Medical College, New York, NY
CURRENT DEVELOPMENTS IN MYELOFIBROSIS TREATMENT
Presented by Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center, Houston, TX
ESSENTIAL THROMBOCYTHEMIA: PATHOGENESIS AND MANAGEMENT
Presented by Jerry L. Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD
WHAT IS THE CLINICAL TRIAL PROCESS?
Presented by Jason Gotlib, MD, MS, Stanford University School of Medicine, Stanford, CA
COMMON COMPLICATIONS OF THE MPNS
Presented by Andrew I. Schafer, MD, Weill Cornell Medical College, New York, NY
WHAT CAN I EXPECT FROM MY MPN TREATMENT?
Presented by Ruben A. Mesa, MD, FACP, Mayo Clinic Cancer Center, Scottsdale, AZ